#USA #West Chester #Centinel Spine #prodisc #Total Disc Replacement

Centinel Spine Reports Significant Growth in prodisc Total Disc Replacement

In the competitive landscape of spinal medical devices, Centinel Spine, LLC has announced an outstanding performance for the third quarter of 2025. The company reported a remarkable 42% increase in prodisc Total Disc Replacement (TDR) revenue, surpassing $30 million for the second consecutive quarter. This achievement reflects a broader trend of growth within the spine industry, particularly in total disc replacement, which has emerged as one of the most dynamic segments in orthopedic implants.

In detail, the quarterly report revealed that prodisc Cervical TDR generated nearly $20 million, marking a 34% year-over-year increase. Additionally, prodisc Lumbar TDR revenues reached over $12 million, which is an impressive 58% rise compared to the previous year. This data underlines Centinel Spine's robust market presence and operational capabilities that drive such exceptional growth.

Operational Highlights

The quarter was not just about financial success; it also marked several operational milestones that contribute to Centinel Spine's ongoing success. On October 10, 2025, the company received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for two-level indications for its prodisc C Vivo and prodisc C SK devices. This approval is crucial as it allows for broader applications of their technology in spinal surgeries, making it more accessible to a larger segment of patients who require cervical disc replacements.

Furthermore, the company achieved a record number of U.S. prodisc surgeon users, surpassing 940 surgeons—a nearly 50% increase from the previous year. This surge in adoption can be attributed to the effectiveness of their products and the growing awareness amongst medical professionals of the benefits provided by prodisc technology. In August 2025, Centinel Spine also secured EU Medical Device Regulation (MDR) certification for the prodisc C Vivo and prodisc C Nova cervical TDR systems, further solidifying its reputation as a global leader in medical devices focused exclusively on spinal solutions.

Leadership Insights

Steve Murray, CEO of Centinel Spine, expressed confidence in the company's trajectory, stating, “Our continued momentum reflects the exceptional dedication of our team and the growing global demand for our prodisc technology.” Under Murray's leadership, the company has consistently achieved double-digit EBITDA margins for four consecutive quarters, reinforcing its market strength and operational efficiency.

As the industry looks forward to Q4 2025, the company anticipates further revenue growth, particularly following the recent FDA approvals. This enables Centinel Spine to expand its market reach and improve patient outcomes through its advanced TDR solutions.

Conclusion

Centinel Spine’s impressive 42% revenue growth in the third quarter of 2025 underscores its commitment to innovation and excellence in spinal care. With strong financial results, expanding surgeon adoption, and critical regulatory approvals, the company is strategically positioned to continue leading the market in total disc replacement innovations. As further advancements are made, Centinel Spine is set to play a pivotal role in transforming spinal surgery, ensuring better outcomes for patients worldwide.